HRP20040912B1 - Novi 1,2,3-supstituirani indolizinski derivati, inhibitori fgf, postupak za njihovo dobivanje i farmaceutski pripravci koji ih sadrže - Google Patents

Novi 1,2,3-supstituirani indolizinski derivati, inhibitori fgf, postupak za njihovo dobivanje i farmaceutski pripravci koji ih sadrže

Info

Publication number
HRP20040912B1
HRP20040912B1 HRP20040912AA HRP20040912A HRP20040912B1 HR P20040912 B1 HRP20040912 B1 HR P20040912B1 HR P20040912A A HRP20040912A A HR P20040912AA HR P20040912 A HRP20040912 A HR P20040912A HR P20040912 B1 HRP20040912 B1 HR P20040912B1
Authority
HR
Croatia
Prior art keywords
sub
alk
coor
fgfs
inhibitors
Prior art date
Application number
HRP20040912AA
Other languages
English (en)
Inventor
Alain Badorc
Françoise Bono
Marie-Françoise Bordes
Nathalie Guillo
Jean-Marc Herbert
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of HRP20040912A2 publication Critical patent/HRP20040912A2/hr
Publication of HRP20040912B1 publication Critical patent/HRP20040912B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<IMAGE NAME="20040912_01" TYPE="jpg" CENTER=TRUE/><BR/>Izum se odnosi na derivate formule (I), gdje R<SUB>1</SUB> predstavlja -OH, (C<SUB>1</SUB>-C<SUB>5</SUB>) alkoksi, karbonil, (C<SUB>2</SUB>-C<SUB>6</SUB>) alkoksikarbonil, -NR<SUB>5</SUB>R<SUB>6</SUB>, -NH-SO<SUB>2</SUB>-Alk, -NH-SO<SUB>2</SUB>-Ph, -NH-CO-Ph, -N(Alk) -CO-Ph, -NH-CO-NH-Ph, -NH-CO-Alk, -NH-CO<SUB>2</SUB>-alk, -O-(CH<SUB>2</SUB>)<SUB>n</SUB>-cAlk, -O-Alk-COOR<SUB>7</SUB>, -O-Alk-O-R<SUB>8</SUB>, -O-Alk-OH, -O-Alk-C(NH<SUB>2</SUB>):NOH, -O-Alk-NR<SUB>5</SUB>R<SUB>6</SUB>, -O-Alk-CN, -O-(CH<SUB>2</SUB>)<SUB>n</SUB>-Ph, -O-Alk-CO-NR<SUB>5</SUB>R<SUB>6</SUB>, -CO-NH-(CH<SUB>2</SUB>)<SUB>m</SUB>-COOR<SUB>7</SUB>, -CO-NH-Alk; R<SUB>2</SUB> predstavlja H, (C<SUB>1</SUB>-C<SUB>5</SUB>) alkil, (C<SUB>1</SUB>-C<SUB>5</SUB>) alkil halid, (C<SUB>3</SUB>-C<SUB>6</SUB>) cikloalkil ili fenil koji je po izboru supstituiran; A predstavlja -CO-, -SO- ili -SO<SUB>2</SUB>-, R<SUB>3</SUB> i R<SUB>4</SUB>, jednaki ili različiti svaki predstavlja H, (C<SUB>1</SUB>-C<SUB>5</SUB>) alkoksil, amino, karboksil, (C<SUB>2</SUB>-C<SUB>6</SUB>) alkoksikarbonil, -OH, nitro, hidroksiamino, -Alk-COOR<SUB>7</SUB>, -NR<SUB>5</SUB>R<SUB>6</SUB>, -NH-Alk-COOR<SUB>7</SUB>, -NH-COO-Alk, -N(R<SUB>11</SUB>) -SO<SUB>2</SUB>-Alk-NR<SUB>9</SUB>R<SUB>10</SUB>, -N(R<SUB>11</SUB>) -SO<SUB>2</SUB>-Alk, -N(R<SUB>11</SUB>) -Alk-NR<SUB>5</SUB>R<SUB>6</SUB>, -N(R<SUB>11</SUB>)-CO-Alk-NR<SUB>9</SUB>R<SUB>10</SUB>, -N(R<SUB>11</SUB>) -CO-Alk, -N(R<SUB>11</SUB>)-CO-CF<SUB>3</SUB>, -NH-Alk-HetN, -O-Alk-NR<SUB>9</SUB>R<SUB>10</SUB>, -O-Alk-CO-NR<SUB>5</SUB>R<SUB>6</SUB>, -O-Alk-HetN, ili R<SUB>3</SUB> i R<SUB>4</SUB> oblikuju zajedno nezasićeni heterocikl od 5 do 6 članova, po izboru u obliku jedne od njihovih farmaceutski prihvatljivih soli.
HRP20040912AA 2002-04-04 2004-10-04 Novi 1,2,3-supstituirani indolizinski derivati, inhibitori fgf, postupak za njihovo dobivanje i farmaceutski pripravci koji ih sadrže HRP20040912B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204220A FR2838123B1 (fr) 2002-04-04 2002-04-04 Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
PCT/FR2003/001030 WO2003084956A1 (fr) 2002-04-04 2003-04-02 NOUVEAUX DERIVES D'INDOLIZINE 1,2,3 SUBSTITUEE, INHIBITEURS DES FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

Publications (2)

Publication Number Publication Date
HRP20040912A2 HRP20040912A2 (en) 2004-12-31
HRP20040912B1 true HRP20040912B1 (hr) 2012-10-31

Family

ID=28052118

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040912AA HRP20040912B1 (hr) 2002-04-04 2004-10-04 Novi 1,2,3-supstituirani indolizinski derivati, inhibitori fgf, postupak za njihovo dobivanje i farmaceutski pripravci koji ih sadrže

Country Status (34)

Country Link
US (2) US7442708B2 (hr)
EP (1) EP1495023B1 (hr)
JP (1) JP4741799B2 (hr)
KR (1) KR101022138B1 (hr)
CN (1) CN100413863C (hr)
AR (1) AR040404A1 (hr)
AT (1) ATE304013T1 (hr)
AU (1) AU2003240984B2 (hr)
BR (1) BR0309026A (hr)
CA (1) CA2476056C (hr)
CO (1) CO5631442A2 (hr)
DE (1) DE60301570T2 (hr)
DK (1) DK1495023T3 (hr)
EA (1) EA007902B1 (hr)
EC (1) ECSP045338A (hr)
ES (1) ES2247540T3 (hr)
FR (1) FR2838123B1 (hr)
HK (1) HK1074631A1 (hr)
HR (1) HRP20040912B1 (hr)
IL (2) IL163755A0 (hr)
IS (1) IS2475B (hr)
MA (1) MA27297A1 (hr)
ME (2) MEP22508A (hr)
MX (1) MXPA04009639A (hr)
NO (1) NO329025B1 (hr)
NZ (1) NZ534786A (hr)
PL (1) PL215265B1 (hr)
RS (1) RS51399B (hr)
SI (1) SI1495023T1 (hr)
TN (1) TNSN04188A1 (hr)
TW (1) TWI335222B (hr)
UA (1) UA78016C2 (hr)
WO (1) WO2003084956A1 (hr)
ZA (1) ZA200406613B (hr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.
US20070269414A1 (en) * 2003-11-04 2007-11-22 Shinji Okano Method for Producing Gene Transferred Denritic Cells
FR2865934B1 (fr) * 2004-02-05 2006-05-05 Sanofi Synthelabo Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
EP1775343A4 (en) * 2004-06-24 2007-11-14 Dnavec Research Inc ANTICANCER AGENTS CONTAINING A DENDRITIC CELL IN WHICH RNA VIRUSES HAVE BEEN TRANSFERRED
CA2587210A1 (en) * 2004-11-22 2006-06-01 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer agents and prodrugs thereof
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
FR2896247B1 (fr) * 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
EP1891955A1 (en) * 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
EP2331541B1 (en) * 2008-09-04 2015-04-22 Boehringer Ingelheim International GmbH Indolizine inhibitors of leukotriene production
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
EP2270043A1 (en) * 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
CN101648953B (zh) * 2009-09-24 2012-09-05 绍兴文理学院 一种咪唑并[1，2-b]吡咯并[1，2-f]哒嗪衍生物及其制备方法和用途
FR2962437B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
FR2967412B1 (fr) * 2010-11-17 2012-12-14 Sanofi Aventis Nouveaux derives d'indolizine, leur preparation et leur application en therapeutique
FR2985258A1 (fr) * 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
US10065955B2 (en) * 2014-12-10 2018-09-04 Ono Pharmaceutical Co., Ltd. Dihydroindolizinone derivative
EP3318563A1 (en) * 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
CN108864083B (zh) * 2018-06-07 2021-05-25 广东药科大学 一类具有抗癌活性的氨基取代吲嗪类化合物及其衍生物
CN110251513A (zh) * 2019-07-03 2019-09-20 南京大学 一种含吡唑的中氮茚化合物在制备抗肿瘤药物中的应用
US11976066B1 (en) 2023-10-23 2024-05-07 King Faisal University Substituted 7-amino-3-(substituted benzoyl)indolizine-1-carboxylates as anti-tubercular agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0097636A1 (fr) * 1982-06-17 1984-01-04 Elf Sanofi Nouveaux dérivés d'indolizine, leur procédé de préparation ainsi que les compositions thérapeutiques les contenant
EP0235111A1 (fr) * 1986-02-14 1987-09-02 Sanofi S.A. Dérivés d'indolizine, leur procédé de préparation ainsi que les compositions les contenant
WO2000071129A1 (en) * 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) * 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
US4378362A (en) * 1979-12-06 1983-03-29 S.A. Labaz N.V. Indolizine derivatives and process for preparing the same
GB9318790D0 (en) * 1993-09-10 1993-10-27 Fujisawa Pharmaceutical Co Heterocyclic derivatives
WO2002098876A1 (en) * 2001-06-06 2002-12-12 Vertex Pharmaceuticals Incorporated Cak inhibitors and uses thereof
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0097636A1 (fr) * 1982-06-17 1984-01-04 Elf Sanofi Nouveaux dérivés d'indolizine, leur procédé de préparation ainsi que les compositions thérapeutiques les contenant
EP0235111A1 (fr) * 1986-02-14 1987-09-02 Sanofi S.A. Dérivés d'indolizine, leur procédé de préparation ainsi que les compositions les contenant
WO2000071129A1 (en) * 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases

Also Published As

Publication number Publication date
KR20040099388A (ko) 2004-11-26
ME00118B (me) 2010-10-10
ATE304013T1 (de) 2005-09-15
ZA200406613B (en) 2007-12-27
IS2475B (is) 2008-12-15
AU2003240984B2 (en) 2008-07-31
ECSP045338A (es) 2005-03-10
BR0309026A (pt) 2005-02-09
SI1495023T1 (sl) 2005-12-31
AR040404A1 (es) 2005-04-06
TNSN04188A1 (fr) 2007-03-12
CO5631442A2 (es) 2006-04-28
US20090023770A1 (en) 2009-01-22
DE60301570D1 (de) 2005-10-13
PL372812A1 (en) 2005-08-08
CN100413863C (zh) 2008-08-27
US7803811B2 (en) 2010-09-28
US7442708B2 (en) 2008-10-28
CA2476056C (fr) 2012-03-06
TW200306181A (en) 2003-11-16
IL163755A (en) 2010-11-30
AU2003240984A1 (en) 2003-10-20
EP1495023B1 (fr) 2005-09-07
IS7413A (is) 2004-08-19
FR2838123A1 (fr) 2003-10-10
ES2247540T3 (es) 2006-03-01
WO2003084956A1 (fr) 2003-10-16
DE60301570T2 (de) 2006-05-18
EA007902B1 (ru) 2007-02-27
NO20044156L (no) 2005-01-03
TWI335222B (en) 2011-01-01
KR101022138B1 (ko) 2011-03-17
MXPA04009639A (es) 2005-07-13
DK1495023T3 (da) 2005-12-27
JP2005532286A (ja) 2005-10-27
US20050203126A1 (en) 2005-09-15
UA78016C2 (uk) 2007-02-15
CA2476056A1 (fr) 2003-10-16
MA27297A1 (fr) 2005-05-02
FR2838123B1 (fr) 2005-06-10
RS51399B (en) 2011-02-28
NO329025B1 (no) 2010-08-02
HRP20040912A2 (en) 2004-12-31
RS86404A (en) 2006-12-15
PL215265B1 (pl) 2013-11-29
EP1495023A1 (fr) 2005-01-12
HK1074631A1 (en) 2005-11-18
MEP22508A (en) 2010-06-10
JP4741799B2 (ja) 2011-08-10
CN1649867A (zh) 2005-08-03
IL163755A0 (en) 2005-12-18
NZ534786A (en) 2006-06-30
EA200400994A1 (ru) 2005-06-30

Similar Documents

Publication Publication Date Title
HRP20040912B1 (hr) Novi 1,2,3-supstituirani indolizinski derivati, inhibitori fgf, postupak za njihovo dobivanje i farmaceutski pripravci koji ih sadrže
HRP20060100T3 (hr) Derivati diaril i arilheteroaril uree kao modulatori 5-ht2a serotonin receptora korisni za profilaksu i liječenje poremećaja povezanih s njima
SI9520084B (sl) Uporaba hetrocikličnih spojin kot dopamin-d3-ligandov
RS52865B (en) Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors
MEP43508A (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
ME00566A (en) Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
HRP20050213A2 (en) 2,4-substituted indoles and their use as 5-ht6 modulators
HRP20080592T3 (hr) DERIVATI 3-FENIL-PIRAZOLA KAO MODULATORI 5-HT-2a SEROTONIN RECEPTORA KORISNI ZA LIJEČENJE POREMEĆAJA POVEZANIH S NJIMA
RS52225B (en) SYNERGETIC HERBICIDE PROCEDURES AND MIXTURES
RS52099B (en) SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS
CY1107974T1 (el) Παραγωγα κινολινης και κιναζολινης εχοντα συναφεια προς τους υποδοχεις τυπου 5ht1
EA202090658A1 (ru) Ингибиторы кэп-зависимой эндонуклеазы
AR037465A1 (es) Compuesto derivado de 5-sulfanil-4h-1,2,4-triazol, composicion farmaceutica que lo comprende y proceso para su preparacion en fase liquida
EA200200942A1 (ru) Фармацевтические композиции, содержащие производные 3-аминоазетидина, новые производные и способ их получения
ME00131B (me) Derivati hinolina i njihova upotreba kao mikobakterijskih inhibitora
SI20744B (sl) Derivati karboksilne kisline, ki inhibirajo vezavo integrinov na njihove receptorje
RS54894B1 (sr) Derivati benzotiofena supstituisani piperazinom kao antipsihotipna sredstva
MEP10709A (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-alpha]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
HRP20050775A2 (en) Quinolinone/benzoxazinone derivatives and uses thereof
CY1105752T1 (el) Παραγωγα ιμιδαζοπυριδινης μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα πepιεχουν
AR021354A1 (es) Procedimiento para la preparacion de un compuesto derivado de quinolina y un procedimiento para preparar una composicion farmaceutica
RS52515B (en) QUICKLY DISSOCATING DOPAMIN 2 RECEPTOR ANTAGONISTS
CO4950515A1 (es) Nuevos derivados de la quinolina para uso medicinal
WO2004071389A3 (en) Non-steroidal infalmmation inhibitors
TR199903310A2 (xx) Aril karboksilik asit ve tetrazol t�revleri.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20150305

Year of fee payment: 13

PBON Lapse due to non-payment of renewal fee

Effective date: 20160402